Insud Pharma
Jonatan Goyeneche Balda currently holds the position of Global Reporting and FP&A at Insud Pharma since March 2022. Previously, Jonatan served as Associate Manager at Accenture España from June 2019 to March 2022, and before that as Senior Consultant in Management Consulting at KPMG España from May 2017 to June 2019. Jonatan began consulting at Deloitte in November 2014, focusing on implementation and maintenance of SAP BPC for financial consolidation and budgeting. Additionally, Jonatan held leadership roles as Secretary General at ELSA Spain and ELSA Deusto, while also working as an economics tutor at Universidad de Deusto during their studies. Jonatan earned a Dual Degree in Business Administration and Law from the University of Deusto, graduating in 2014.
This person is not in the org chart
Insud Pharma
5 followers
INSUD PHARMA operates across the entire pharmaceutical value chain, delivering specialized expertise and experience in scientific research, development, manufacturing, sales and marketing of a wide range of value-adding active pharmaceutical ingredients (APIs), finished dosage forms (FDFs) and branded pharmaceuticals, for human and animal health. While the main offices are located in Madrid, Lugano, Buenos Aires, INSUD PHARMA is acting worldwide, creating a broad and balanced manufacturing and commercial network across Europe, America, Asia and Africa, to address global opportunities and customers` needs in all major pharmaceutical markets. INSUD PHARMA's activity is organized in three synergistic business areas: Industrial (Chemo), Branded (Exeltis) and Biotech (mAbxience), with over 7,300 professionals in more than 50 countries, 18 state-of-the-art facilities, 15 specialized R&D centers, 12 commercial offices and more than 35 pharmaceutical affiliates, serving 1,150 customers in 96 countries around the world. INSUD PHARMA believes in innovation and sustainable development. Our commitment is to improve people`s health and quality of life, providing access to quality medicines at affordable prices, and to continuously expand our efforts and R&D investment to develop new and better therapies.